Position in ABVX
as of Jun 30, 2026
· filed Jul 15, 2026
Position Value
$85,686
New position
Shares Held
643
first reported quarter
Ownership
0.001%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#7
of 17 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Derivatives in ABVX
reported options exposure · as of Jun 30, 2026CallValue
$226,542
CallShares
1,700
PutValue
$39,978
PutShares
300
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026RFG Advisory, LLC holds $11,845,532 across 11 Biotechnology names. ABVX ranks #8 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VKTX |
Viking Therapeutics, Inc.
|
142,790 | $5,570,237 | |
| 2 | CPRX |
Catalyst Pharmaceuticals, Inc.
|
85,989 | $2,702,634 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
19,613 | $1,535,109 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,989 | $987,995 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
789 | $491,973 | |
| 6 | INCY |
Incyte Corp
|
2,120 | $240,323 | |
| 7 | PRQR |
ProQR Therapeutics N.V.
|
64,000 | $119,040 | |
| 8 | ABVX |
Abivax S.A.
This page
|
643 | $85,686 |
All Filings in ABVX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $85,686 | 643 | Shares | Sole | 2026-07-15 | |
| 2026-06-30 | $226,542 | 1,700 | Call | Sole | 2026-07-15 | |
| 2026-06-30 | $39,978 | 300 | Put | Sole | 2026-07-15 | |
| No filing history on record for this holder in this stock. | ||||||